40 pharma firms showed interested to produce 2-DG drug: ASG

·2-min read

Chennai, June 25 (PTI) The Madras High Court was told on Friday that 40 pharmaceutical firms had shown interest in manufacturing 2-deoxy-D-Glucose (2-DG) an adjunct drug used in COVID-19 treatment.

The anti-COVID-19 therapeutic application of 2-DG has been developed by the Institute of Nuclear Medicine and Allied Sciences (INMAS), a leading laboratory of the Defence Research and Development Organisation (DRDO), in collaboration with Hyderabad-based Dr Reddy's Laboratories.

Additional Solicitor General R Sankaranarayanan made the submission before the second bench of Justices N Kirubakaran and T V Tamilselvi on a PIL petition from D Saravanan of Chennai.

The petitioner complained that DRDO had given licence to Dr Reddys Laboratories in Hyderabad alone for producing the oral powder at a cost of Rs 990 per sachet of 2.34 grams and not to any other pharma company in the country.

The ASG said DRDO had invited Expression of Interest to produce the drug and so far 40 pharmaceutical companies had shown interest.

The DRDO was highly capable of ensuring that the drug is manufactured in large quantities within the shortest possible time.

It had fixed June 17 as the last date for submitting an Expression of Interest to manufacture the drug and 40 companies had responded.

After telling the ASG to circulate all documents and recording his submissions, the bench reserved its verdict.

The court also took note of a submission by a litigant that the DRDO's drug was very effective and that a woman COVID-19 patient, with comorbidities had a 'magical cure' after being administered with 30 sachets of the drug.

He said the doctor who treated the patient was also ready to vouch for its efficacy and the bench recorded its appreciation to the doctor concerned. PTI COR SA APR ADMINISTRATOR APR ADMINISTRATOR

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting